Index RUT
P/E -
EPS (ttm) -1.07
Insider Own 27.68%
Shs Outstand 32.52M
Perf Week 20.18%
Market Cap 236.26M
Forward P/E -
EPS next Y -0.96
Insider Trans -0.16%
Shs Float 24.94M
Perf Month 22.32%
Income -34.78M
PEG -
EPS next Q -0.33
Inst Own 56.28%
Short Float 5.36%
Perf Quarter -5.26%
Sales 50.73M
P/S 4.66
EPS this Y 1.42%
Inst Trans 3.34%
Short Ratio 5.93
Perf Half Y 5.55%
Book/sh 4.77
P/B 1.44
EPS next Y 13.64%
ROA -17.04%
Short Interest 1.34M
Perf Year -4.99%
Cash/sh 3.89
P/C 1.76
EPS next 5Y -
ROE -20.61%
52W Range 4.85 - 12.51
Perf YTD -38.95%
Dividend Est. -
P/FCF -
EPS past 5Y -31.19%
ROI -21.70%
52W High -45.24%
Beta 1.10
Dividend TTM -
Quick Ratio 7.53
Sales past 5Y 21.26%
Gross Margin 46.13%
52W Low 41.24%
ATR (14) 0.41
Dividend Ex-Date -
Current Ratio 8.37
EPS Y/Y TTM 7.26%
Oper. Margin -83.26%
RSI (14) 63.36
Volatility 8.73% 6.28%
Employees 230
Debt/Eq 0.03
Sales Y/Y TTM 5.62%
Profit Margin -68.56%
Recom 1.00
Target Price 15.33
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q 14.87%
Payout -
Rel Volume 0.62
Prev Close 6.88
Sales Surprise 7.52%
EPS Surprise 8.84%
Sales Q/Q 5.31%
Earnings Apr 30 BMO
Avg Volume 225.50K
Price 6.85
SMA20 15.76%
SMA50 8.33%
SMA200 -0.22%
Trades
Volume 139,393
Change -0.44%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-07-23 Initiated
Stephens
Overweight
$14
Oct-15-21 Resumed
Cowen
Outperform
Jan-12-21 Initiated
William Blair
Outperform
Jan-12-21 Initiated
SVB Leerink
Outperform
$70
Jan-12-21 Initiated
Stifel
Buy
$65
Jan-12-21 Initiated
Cowen
Outperform
May-15-24 07:00AM
May-14-24 09:55AM
May-09-24 09:35AM
May-01-24 08:49AM
03:09AM
12:08AM
Loading…
12:08AM
(Thomson Reuters StreetEvents)
Apr-30-24 11:53AM
09:35AM
08:55AM
07:45AM
07:30AM
Apr-23-24 07:00AM
Mar-12-24 07:00AM
Mar-07-24 12:02PM
Mar-05-24 07:33AM
07:00AM
Loading…
07:00AM
Feb-29-24 07:00AM
Feb-22-24 07:00AM
Feb-20-24 07:00AM
Feb-02-24 11:01PM
Dec-28-23 12:00PM
Dec-27-23 10:30AM
Dec-22-23 01:01PM
Dec-19-23 09:55AM
Dec-18-23 05:34AM
Nov-14-23 07:00AM
Nov-09-23 03:37PM
Nov-07-23 08:14AM
07:00AM
Nov-06-23 04:30PM
07:00AM
Loading…
Oct-31-23 07:00AM
Oct-24-23 04:30PM
07:00AM
Sep-26-23 07:00AM
Sep-18-23 07:00AM
Sep-15-23 07:00AM
Aug-26-23 07:50AM
Aug-08-23 09:15AM
07:00AM
Aug-07-23 07:00AM
Jul-31-23 07:00AM
Jul-25-23 07:00AM
Jul-16-23 08:42AM
Jul-13-23 05:42AM
May-30-23 07:00AM
May-23-23 09:54AM
07:00AM
May-09-23 08:25AM
07:00AM
May-04-23 07:00AM
Apr-26-23 07:00AM
Apr-25-23 07:00AM
Apr-18-23 11:14AM
Mar-08-23 02:22AM
(Thomson Reuters StreetEvents)
Mar-07-23 08:25AM
07:00AM
Feb-27-23 06:05PM
Feb-21-23 07:00AM
Feb-14-23 07:00AM
Feb-07-23 01:37PM
Feb-06-23 05:16AM
Jan-17-23 07:00AM
Dec-29-22 06:02AM
Dec-07-22 07:00AM
Nov-16-22 06:24AM
Nov-14-22 11:44AM
10:05AM
07:00AM
Nov-10-22 07:00AM
Nov-09-22 07:00AM
Nov-02-22 07:00AM
Oct-19-22 07:00AM
Oct-12-22 05:00PM
Sep-29-22 07:50AM
Aug-09-22 04:00PM
08:45AM
07:30AM
07:00AM
Jul-27-22 07:00AM
Jul-25-22 07:21AM
Jul-19-22 07:00AM
Jun-13-22 04:22PM
Jun-02-22 07:00AM
May-26-22 07:00AM
May-11-22 02:30AM
May-10-22 08:15AM
07:00AM
May-09-22 07:00AM
May-03-22 07:00AM
Apr-21-22 07:00AM
Apr-12-22 05:37PM
07:00AM
Mar-08-22 05:58PM
Mar-07-22 10:30PM
05:15PM
04:05PM
Mar-02-22 04:30PM
Feb-15-22 07:00AM
Feb-14-22 12:24PM
Feb-08-22 07:00AM
908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Knopp Kevin J. President and CEO May 13 '24 Buy 6.42 10,000 64,200 508,981 May 13 04:42 PM Knopp Kevin J. President and CEO May 10 '24 Buy 5.77 10,000 57,700 498,981 May 10 06:36 PM Knopp Kevin J. President and CEO May 09 '24 Buy 5.83 10,000 58,300 488,981 May 09 04:34 PM Knopp Kevin J. President and CEO May 08 '24 Buy 5.72 10,000 57,200 478,981 May 08 09:31 PM Knopp Kevin J. President and CEO May 07 '24 Buy 5.60 10,000 56,000 468,981 May 07 06:07 PM Knopp Kevin J. President and CEO Apr 16 '24 Option Exercise 1.75 47,000 82,250 458,981 Apr 16 04:11 PM Brown Christopher D. Chief Product Officer Apr 01 '24 Option Exercise 1.75 3,600 6,300 884,994 Apr 02 04:06 PM Griffith Joseph H. IV Chief Financial Officer Mar 26 '24 Option Exercise 1.58 8,437 13,330 93,437 Mar 27 04:16 PM Griffith Joseph H. IV Chief Financial Officer Feb 02 '24 Sale 7.09 9,711 68,873 80,000 Feb 02 07:10 PM Knopp Kevin J. President and CEO Feb 01 '24 Sale 7.00 9,071 63,461 411,981 Feb 02 04:39 PM Griffith Joseph H. IV Chief Financial Officer Feb 01 '24 Sale 7.00 5,698 39,892 89,711 Feb 02 07:10 PM Turner Michael S. Chief Legal & Admin Officer Feb 01 '24 Sale 6.99 5,232 36,559 9,105 Feb 02 04:40 PM Brown Christopher D. Chief Product Officer Feb 01 '24 Sale 7.01 3,957 27,730 886,394 Feb 02 04:37 PM Griffith Joseph H. IV Chief Financial Officer Dec 28 '23 Sale 12.08 6,000 72,480 80,000 Jan 02 05:01 PM Brown Christopher D. Chief Product Officer Dec 21 '23 Sale 9.12 7,370 67,214 877,905 Dec 21 04:46 PM Brown Christopher D. Chief Product Officer Dec 20 '23 Sale 9.10 5,235 47,638 885,275 Dec 21 04:46 PM Brown Christopher D. Chief Product Officer Dec 19 '23 Sale 9.08 7,395 67,147 890,510 Dec 21 04:46 PM Griffith Joseph H. IV Chief Financial Officer Dec 19 '23 Sale 9.08 5,580 50,666 86,000 Dec 21 04:47 PM Brown Christopher D. Chief Product Officer Jun 07 '23 Sale 10.03 4,470 44,834 897,905 Jun 09 04:17 PM Knopp Kevin J. President and CEO Jun 05 '23 Option Exercise 1.75 28,500 49,875 396,348 Jun 05 04:07 PM Knopp Kevin J. President and CEO May 23 '23 Sale 10.12 60,000 607,200 367,848 May 25 04:08 PM Brown Christopher D. Chief Technology Officer May 23 '23 Sale 10.02 10,000 100,200 892,375 May 25 04:12 PM
Index -
P/E -
EPS (ttm) -5.01
Insider Own 25.59%
Shs Outstand 26.45M
Perf Week 9.66%
Market Cap 145.68M
Forward P/E -
EPS next Y -2.60
Insider Trans 14.80%
Shs Float 19.89M
Perf Month 15.47%
Income -144.49M
PEG -
EPS next Q -0.77
Inst Own 54.76%
Short Float 7.30%
Perf Quarter -24.09%
Sales 6.98M
P/S 20.87
EPS this Y 58.31%
Inst Trans 86.41%
Short Ratio 7.35
Perf Half Y 79.28%
Book/sh 0.56
P/B 9.67
EPS next Y -7.18%
ROA -84.98%
Short Interest 1.45M
Perf Year 33.58%
Cash/sh 4.05
P/C 1.35
EPS next 5Y -
ROE -237.24%
52W Range 2.09 - 8.17
Perf YTD -30.04%
Dividend Est. -
P/FCF -
EPS past 5Y 21.16%
ROI -230.63%
52W High -33.29%
Beta 1.71
Dividend TTM -
Quick Ratio 3.01
Sales past 5Y 128.79%
Gross Margin 73.04%
52W Low 160.74%
ATR (14) 0.34
Dividend Ex-Date -
Current Ratio 3.01
EPS Y/Y TTM 48.06%
Oper. Margin -1779.23%
RSI (14) 53.77
Volatility 6.42% 5.94%
Employees 68
Debt/Eq 4.09
Sales Y/Y TTM -43.55%
Profit Margin -2069.80%
Recom 1.00
Target Price 19.25
Option/Short Yes / Yes
LT Debt/Eq 3.16
EPS Q/Q 88.87%
Payout -
Rel Volume 0.83
Prev Close 5.48
Sales Surprise -100.00%
EPS Surprise 88.20%
Sales Q/Q -100.00%
Earnings May 14 BMO
Avg Volume 197.46K
Price 5.45
SMA20 5.70%
SMA50 -0.98%
SMA200 11.60%
Trades
Volume 163,176
Change -0.55%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-04-20 Upgrade
H.C. Wainwright
Neutral → Buy
$11 → $15
Sep-22-20 Initiated
Alliance Global Partners
Buy
$18
Jan-17-20 Downgrade
Wedbush
Outperform → Neutral
Mar-08-19 Resumed
JMP Securities
Mkt Outperform
$18
Feb-14-19 Resumed
Oppenheimer
Outperform
$13
Nov-05-18 Upgrade
ROTH Capital
Neutral → Buy
Mar-13-18 Reiterated
Wedbush
Outperform
$11 → $13
Oct-31-17 Resumed
Piper Jaffray
Overweight
$30
Oct-23-17 Initiated
ROTH Capital
Neutral
$15
Aug-10-17 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
May-15-24 03:03AM
01:14AM
(Thomson Reuters StreetEvents)
May-14-24 10:52AM
07:30AM
May-07-24 09:00AM
07:00AM
Loading…
07:00AM
May-01-24 10:01AM
Apr-10-24 09:49AM
08:30AM
Apr-09-24 07:00AM
Apr-02-24 04:30PM
Mar-28-24 10:06AM
Mar-27-24 11:53AM
07:30AM
Mar-25-24 07:00AM
07:00AM
Loading…
Mar-20-24 07:00AM
Feb-27-24 07:00AM
Jan-31-24 04:00PM
Jan-19-24 10:43AM
Jan-18-24 12:00PM
Jan-17-24 08:50AM
Jan-16-24 12:00PM
09:55AM
Jan-11-24 08:48AM
Jan-08-24 07:00AM
Jan-03-24 11:03PM
Dec-19-23 07:27AM
Dec-07-23 09:44AM
Dec-06-23 07:00AM
Dec-03-23 04:17PM
07:30AM
Loading…
Nov-21-23 07:30AM
Nov-15-23 01:08PM
Nov-14-23 07:30AM
Nov-07-23 07:30AM
Oct-02-23 08:45AM
Sep-07-23 04:30PM
Aug-08-23 09:49PM
(Thomson Reuters StreetEvents)
09:05AM
07:30AM
Aug-04-23 04:30PM
Aug-01-23 07:30AM
Jul-27-23 06:29AM
(American City Business Journals)
Jul-21-23 05:40PM
Jul-05-23 04:30PM
Jun-22-23 08:14PM
Jun-13-23 08:00AM
Jun-08-23 07:30AM
Jun-01-23 04:30PM
May-25-23 05:05PM
08:44AM
May-13-23 10:15AM
May-10-23 10:08PM
(Thomson Reuters StreetEvents) +10.29%
08:45AM
07:30AM
May-09-23 07:00AM
May-07-23 08:40PM
May-03-23 07:30AM
May-02-23 07:00AM
Mar-06-23 09:48AM
Mar-04-23 07:08AM
Mar-02-23 10:02PM
(Thomson Reuters StreetEvents)
09:35AM
07:30AM
Feb-28-23 07:30AM
Feb-23-23 07:30AM
Feb-09-23 04:05PM
Feb-01-23 09:43AM
Jan-26-23 07:00AM
Jan-09-23 07:00AM
Dec-23-22 04:05PM
Dec-16-22 06:47AM
Dec-12-22 07:30AM
Dec-10-22 10:00AM
Dec-05-22 07:00AM
Nov-22-22 07:30AM
Nov-14-22 08:45AM
07:30AM
Nov-07-22 07:30AM
Nov-04-22 04:30PM
Nov-03-22 09:01AM
Oct-05-22 04:01PM
Sep-23-22 12:00PM
Sep-16-22 04:05PM
Sep-15-22 04:13PM
Sep-14-22 01:26PM
Sep-13-22 04:01PM
Sep-07-22 07:30AM
Sep-02-22 04:01PM
Aug-09-22 08:45AM
08:30AM
(Thomson Reuters StreetEvents)
07:30AM
Aug-04-22 04:01PM
Aug-03-22 04:01PM
Aug-02-22 07:30AM
Jul-28-22 10:33AM
(American City Business Journals) -5.67%
Jul-13-22 12:00PM
Jul-06-22 11:31AM
Jul-05-22 04:48PM
(American City Business Journals)
07:59AM
07:00AM
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Roth David Chief Medical Officer Apr 03 '24 Sale 4.95 10,451 51,732 0 Apr 05 04:30 PM Roth David Chief Medical Officer Apr 02 '24 Sale 4.98 150 747 10,451 Apr 02 04:58 PM AKKARAJU SRINIVAS Director Dec 21 '23 Buy 4.42 904,977 3,999,998 1,786,427 Dec 26 05:24 PM Roth David Chief Medical Officer Dec 12 '23 Sale 4.95 6,287 31,121 0 Dec 14 04:24 PM Roth David Chief Medical Officer Dec 06 '23 Sale 3.95 6,287 24,834 6,287 Dec 08 04:23 PM Roth David Chief Medical Officer Jul 31 '23 Sale 3.95 7,348 29,025 0 Aug 02 04:21 PM Olson Eric R Chief Scientific Officer Jul 17 '23 Sale 3.50 689 2,412 6,661 Jul 18 08:27 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite